{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:36:35Z","timestamp":1790663795121,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jdiacomp.2024.108743","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T11:48:41Z","timestamp":1712231321000},"page":"108743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials"],"prefix":"10.1016","volume":"38","author":[{"given":"Wanrun","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunpan","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2024.108743_bb0005","first-page":"S67","article-title":"Diagnosis and classification of diabetes mellitus","volume":"36 Suppl 1(Suppl 1)","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0010","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jama.2020.17738","volume":"325","author":"The Prevention of Diabetes Mellitus","year":"2021","journal-title":"Jama"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-021-01289-4","article-title":"Variability of risk factors and diabetes complications","volume":"20","author":"Ceriello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0030","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","article-title":"Contemporary medical, device, and surgical therapies for obesity in adults","volume":"401","author":"Perdomo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0035","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Pich\u00e9","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.05.013","article-title":"Obesity and hypertension","volume":"122","author":"Seravalle","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0045","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0050","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0055","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cmet.2012.04.001","article-title":"Inflammation and lipid signaling in the etiology of insulin resistance","volume":"15","author":"Glass","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00003495-199300462-00026","article-title":"Diagnosis of insulin resistance","volume":"46","author":"Mart\u00ednez","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11154-012-9229-1","article-title":"Role of insulin resistance in endothelial dysfunction","volume":"14","author":"Muniyappa","year":"2013","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0070","first-page":"1","article-title":"Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training","volume":"3","author":"Roberts","year":"2013","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0075","volume":"12","author":"Smits","year":"2021","journal-title":"Safety of Semaglutide Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.JAA.0000669456.13763.bd","article-title":"Long-acting GLP-1RAs: an overview of efficacy, safety, and their role in type 2 diabetes management","volume":"33","author":"Chun","year":"2020","journal-title":"Jaapa"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of Liraglutide and Semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1467-789X.2009.00623.x","article-title":"Subcutaneous and visceral adipose tissue: structural and functional differences","volume":"11","author":"Ibrahim","year":"2010","journal-title":"Obes Rev"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092358","article-title":"Adipose tissue dysfunction as determinant of obesity-associated metabolic complications","volume":"20","author":"Longo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0115","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1515\/cclm-2018-0801","article-title":"Subcutaneous adipose tissue distribution and telomere length","volume":"57","author":"Mangge","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/imr.12850","article-title":"Visceral adipose tissue Tregs and the cells that nurture them","volume":"295","author":"Li","year":"2020","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2022.10.035","article-title":"Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease","volume":"78","author":"Cholankeril","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0130","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/hep.27382","article-title":"Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis","volume":"61","author":"Xiao","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0135","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/osp4.324","article-title":"Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5)","volume":"5","author":"Ahmadi","year":"2019","journal-title":"Obes Sci Pract"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00125-019-05021-6","article-title":"Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation","volume":"63","author":"Bizino","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0145","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1507\/endocrj.EJ16-0449","article-title":"Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial","volume":"64","author":"Bouchi","year":"2017","journal-title":"Endocr J"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0150","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/dom.14090","article-title":"Liraglutide treatment in overweight and obese patients with type 1 diabetes: a 26-week randomized controlled trial; mechanisms of weight loss","volume":"22","author":"Ghanim","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0160","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/dom.14319","volume":"23","author":"Harreiter","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3292","article-title":"Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"36","author":"Liu","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0170","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1042\/CS20160803","article-title":"GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction","volume":"131","author":"Pastel","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0175","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12933-019-0890-5","article-title":"A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in south Asian type 2 diabetes patients","volume":"18","author":"van Eyk","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0180","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1210\/jc.2015-3906","article-title":"Mechanisms of action of Liraglutide in patients with type 2 diabetes treated with high-dose insulin","volume":"101","author":"Vanderheiden","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0185","doi-asserted-by":"crossref","first-page":"9783859","DOI":"10.1155\/2020\/9783859","article-title":"Effects of Exenatide and Humalog Mix25 on fat distribution, insulin sensitivity, and \u03b2-cell function in Normal BMI patients with type 2 diabetes and visceral adiposity","volume":"2020","author":"Wang","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0190","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12624","article-title":"A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity","volume":"15","author":"Weghuber","year":"2020","journal-title":"Pediatr Obes"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0195","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, Sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0200","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/jdi.13775","article-title":"Effect of glucagon-like peptide-1 receptor agonists on fat distribution in patients with type2 diabetes: a systematic review and meta-analysis","volume":"13","author":"Duan","year":"2022","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0205","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.jdiacomp.2024.108743_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612676","article-title":"Diabetes mellitus secondary to endocrine diseases: an update of diagnostic and treatment particularities","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872724000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872724000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T10:28:39Z","timestamp":1716114519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872724000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1056872724000692"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108743","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108743"}}